BIG PHARMA BETTER THAN BIOTECH?
The headline:Some Big Pharma Starting To Outperform Biotech... Merck (MRK) Shares Rise Despite WSJ Report On Short-Term Vioxx Heart Risks... Dendreon (DNDN) Shares Surge 8% On New Analysis In Cancer Research Journal
CNBC Pharmaceutical Reporter Mike Huckman joins the guys for this conversation.
Huckman says big pharma has been beating big biotech in the last few months.
Pete Najarian recommends buying Bristol-Myers (BMY). He also likes Isis Pharmaceutical (ISIS) as a biotech name.
Jeff Macke likes Genetech (DNA) as an investment. However, he adds this company is long past fast money.
Huckman also says Dendreon (DNDN) shares surged 7% on new analysis in a cancer research journal.
Pete Najarian explains that 200,000 DNDN options traded on Tuesday and reveals that he owns the call options. Pete adds “it’s a very cheap lottery ticket.”
Guy Adami thinks the stock is either going to $0 or $30 and likes it as a risk reward play.
Got something to say? Send us an e-mail at firstname.lastname@example.org and your comment might be posted on the Rapid Recap! Prefer to keep it between us? You can still send questions and comments to email@example.com.
Trader disclosure: On July 3rd 2007, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders
Macke Owns (DIS); Najarian Owns (DNDN), (ERIC), (HLT), (JNPR); Bolling Owns (DIS), (T), (XOM), Natural Gas, Corn